| Similar Articles |
|---|
 |
BusinessWeek
July 18, 2005 |
A Coronary Conundrum Four medical experts weigh in on whether heart surgery prolongs patients' lives or only relieves suffering.   |
The Motley Fool
February 24, 2011
Brian Orelli |
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead. |
The Motley Fool
August 29, 2011
Brian Orelli |
Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
The Motley Fool
July 22, 2005
Karl Thiel |
Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
March 31, 2010
Brian Orelli |
How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain. |
Health
July 2007
Curt Pesmen |
Surgery to Avoid #3: Angioplasty A new study has found that heart medication is just as effective as this invasive surgery. |
The Motley Fool
April 7, 2011
Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
Health
January 2008 |
Should You get a Tummy Tuck? Surgery can help, but it won't replace exercise |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
American Family Physician
March 15, 2003 |
Physical Activity for Healthy Weight How are physical activity, weight, and health related?... How will physical activity help me?... I have a busy life -- how can I find time to exercise?... How do I get started?... What's next? What kind of exercise program should I follow?... etc. |
Nursing
January 2009
Susan Gallagher Camden |
Shedding Health Risks with Bariatric Weight Loss Surgery More obese patients are turning to bariatric weight loss surgery, which is proving its worth by decreasing or eliminating dangerous comorbidities of obesity. Here's how to help prepare your patient for surgery and care for her afterward. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
HBS Working Knowledge
August 10, 2015
Michael Blanding |
New Medical Devices Get To Patients Too Slowly The FDA has streamlined drug testing to ensure new therapies come to market quickly. But when it comes to life-giving medical devices, approvals seem unnecessarily slow, according to research by Ariel Dora Stern. |
American Family Physician
February 1, 2002
Robert J. Nied & Barry Franklin |
Promoting and Prescribing Exercise for the Elderly Physicians play a key role in motivating older patients and advising them regarding their physical limitations and/or comorbidities. Motivating patients to begin exercise is best achieved by focusing on individual patient goals, concerns, and barriers to exercise... |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
American Family Physician
August 1, 2006
McDermott & Mernitz |
Exercise and Older Patients: Prescribing Guidelines A combination of aerobic activity, strength training, and flexibility exercises, plus increased general daily activity can reduce medication dependence and health care costs while maintaining functional independence and improving quality of life in older adults. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
The Motley Fool
July 1, 2011
Alex Crawford |
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review Do these drugs have a chance of FDA approval? |
Fast Company
December 2009
Elizabeth Svoboda |
Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
American Family Physician
November 15, 2000 |
Clinical Briefs Reducing Falls Among Older Women... Physical Activity and Fitness in Schools... Exercise in the Patient with Diabetes Mellitus... Blueprint for Development of Tuberculosis Vaccine... Answers to This Issues' Clinical Quiz... |
Chemistry World
August 5, 2015
Emma Stoye |
Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
September 25, 2007
Brian Orelli |
Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note. |
The Motley Fool
June 17, 2010
Luke Timmerman |
Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials. |
BusinessWeek
July 18, 2005
John Carey |
Is Heart Surgery Worth It? Physicians are questioning whether bypasses and angioplasties necessarily prolong patients' lives. |
American Family Physician
December 15, 2006 |
Exercise: How to Get Started An informative guide: Why should I exercise?... Who should exercise?... What kind of exercise should I do?... How long should I exercise?... etc. |
Salon.com
March 2, 2001
Dawn MacKeen |
Your heart has been recalled In the brave new world of body-part implants, what happens when you get a lemon of a ticker? |
BusinessWeek
June 9, 2009
John Carey |
Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
American Family Physician
February 1, 2002 |
Exercise for the Elderly Is it safe for me to exercise?... How do I get started?... What type of exercise should I do?... When should I call my doctor?... What are some specific exercises I can do?... |
American Family Physician
March 1, 2004 |
Exercise for the Elderly Common questions about exercise for the elderly are answered in this article including safety, types of exercise, and how to get started. |
American Family Physician
July 15, 2000
Valerie Palda |
Editorials PRE-OPportunity Knocks: A Different Way to Think About the Preoperative Evaluation... |
Pharmaceutical Executive
June 1, 2014
Jill Wechsler |
Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D. |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
American Family Physician
May 15, 2001 |
Pain Relief After Surgery How will my pain be managed?...How are pain medicines given after surgery?... What should I do to make sure I receive the best possible pain relief?... |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
April 26, 2011
Luke Timmerman |
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex? |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
American Family Physician
July 15, 2000
Mitchell S. King |
Preoperative Evaluation The purpose of a preoperative evaluation is not to "clear" patients for elective surgery, but rather to evaluate and, if necessary, implement measures to prepare higher risk patients for surgery... |
